Home
      Contact Us | Site Map | SEARCH
 
About HDN
About RHOPHYLAC
The Rhophylac Promise
High Purity
Rapid Performance
Proven Efficacy
Enhanced Safety
Added Convenience
Professional Resources
Ordering/Reimbursement
Patient Education
Request More Information
Important Saftey Information
Prescribing Information
Rhophylac has you covered


The Rhophylac® Promise™ of high purity

Ion-exchange chromatography isolation procedure results in a high-purity product, with a high concentration of IgG1

  • Very low IgA content
    • Below detection limit of 5 mcg/mL
  • Removal of 98% of unwanted protein aggregates
  • Formulated without preservatives, thimerosal (mercury), or latex
  • Low anticomplement activity for improved tolerability2
  • Low sodium content
The Rhophylac® Promise of High Purity

References:
1. Stucki M, Moudry R, Kempf C, et al. Characterisation of a chromatographically produced anti-D immunoglobin product. J Chromatography B. 700; 1997:241-248.
2. Hirose TG, Mays DA. The safety of RhIG in the prevention of haemolytic disease of the newborn. Br J Obstet Gynaecol. 2007;27:545-557.



© CSL Behring 2008. The product information on this site is intended for US residents only.

Important Safety Information

Rhophylac® is indicated for suppression of rhesus (Rh) isoimmunization in:

  • Pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with an Rh-incompatible pregnancy, including routine antepartum and postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetric complications, invasive procedures during pregnancy, or obstetric manipulative procedures.
  • Incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells.

For suppression of Rh isommunization, Rhophylac® can be administered IM or IV.

Rhophylac® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

For postpartum use following an Rh-incompatible pregnancy, Rhophylac® should not be given to the newborn infant.

The most common adverse reactions in the suppression of Rh isoimmunization with Rhophylac® are nausea, dizziness, headache, injection-site pain, and malaise.

Please see full prescribing information.